PL3042658T3 - Kompozycja lecznicza poprawiająca leptynooporność - Google Patents

Kompozycja lecznicza poprawiająca leptynooporność

Info

Publication number
PL3042658T3
PL3042658T3 PL14843063T PL14843063T PL3042658T3 PL 3042658 T3 PL3042658 T3 PL 3042658T3 PL 14843063 T PL14843063 T PL 14843063T PL 14843063 T PL14843063 T PL 14843063T PL 3042658 T3 PL3042658 T3 PL 3042658T3
Authority
PL
Poland
Prior art keywords
medicinal composition
leptin resistance
composition improving
improving leptin
resistance
Prior art date
Application number
PL14843063T
Other languages
English (en)
Inventor
Akira Kakizuka
Ken Ebihara
Megumi ABE
Chihiro EBIHARA
Original Assignee
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University filed Critical Kyoto University
Publication of PL3042658T3 publication Critical patent/PL3042658T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/10Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14843063T 2013-09-04 2014-09-03 Kompozycja lecznicza poprawiająca leptynooporność PL3042658T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013183265 2013-09-04
EP14843063.0A EP3042658B1 (en) 2013-09-04 2014-09-03 Medicinal composition improving leptin resistance
PCT/JP2014/073256 WO2015033981A1 (ja) 2013-09-04 2014-09-03 レプチン抵抗性を改善する医薬組成物

Publications (1)

Publication Number Publication Date
PL3042658T3 true PL3042658T3 (pl) 2019-08-30

Family

ID=52628448

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14843063T PL3042658T3 (pl) 2013-09-04 2014-09-03 Kompozycja lecznicza poprawiająca leptynooporność

Country Status (8)

Country Link
US (1) US9931351B2 (pl)
EP (1) EP3042658B1 (pl)
JP (1) JP6378685B2 (pl)
DK (1) DK3042658T3 (pl)
ES (1) ES2708577T3 (pl)
PL (1) PL3042658T3 (pl)
PT (1) PT3042658T (pl)
WO (1) WO2015033981A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12011438B2 (en) 2018-04-16 2024-06-18 Kyoto University Composition for protecting cardiomyocyte
JP7101982B2 (ja) 2018-07-31 2022-07-19 国立大学法人京都大学 脳梗塞の処置用の医薬組成物
CN114599370A (zh) * 2019-10-24 2022-06-07 国立大学法人京都大学 用于保护软骨的药物组合物
JP7705649B2 (ja) 2021-04-28 2025-07-10 国立大学法人京都大学 皮膚組織の異常を改善するための組成物
WO2023120704A1 (ja) 2021-12-24 2023-06-29 国立大学法人京都大学 心機能を改善するための組成物
KR20250093323A (ko) * 2022-10-27 2025-06-24 가부시키가이샤 교토 소야쿠 겐큐쇼 나프탈렌 유도체의 결정

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO2007041282A2 (en) * 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
DK2599771T3 (en) * 2010-07-30 2016-10-24 Daito Chemix Corp naphthalene
JP5822840B2 (ja) 2010-09-30 2015-11-24 ダイトーケミックス株式会社 眼疾患処置薬
JP6109937B2 (ja) * 2012-07-20 2017-04-05 クリーブ バイオサイエンシズ インコーポレイテッド p97複合体の阻害剤としての融合ピリミジン
DK2959903T3 (en) 2013-02-20 2019-01-21 Univ Kyoto Medicine for the treatment of eye disease

Also Published As

Publication number Publication date
US20160303144A1 (en) 2016-10-20
DK3042658T3 (en) 2019-04-23
PT3042658T (pt) 2019-05-13
EP3042658B1 (en) 2019-01-16
EP3042658A1 (en) 2016-07-13
US9931351B2 (en) 2018-04-03
EP3042658A4 (en) 2017-03-29
JP6378685B2 (ja) 2018-08-22
WO2015033981A1 (ja) 2015-03-12
JPWO2015033981A1 (ja) 2017-03-02
ES2708577T3 (es) 2019-04-10

Similar Documents

Publication Publication Date Title
IL286759A (en) Therapeutic methods and preparations
ZA201506487B (en) Therapeutic compounds and compositions
IL246377A0 (en) Pharmaceutical preparations for oral administration
GB201317286D0 (en) Composition and Use
SG11201508167PA (en) Therapeutic compositions and uses thereof
IL241254A0 (en) Pharmaceutical preparations containing everolimus
ZA201403276B (en) Low dose pharmaceutical composition
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201318489D0 (en) Composition
SG11201510442TA (en) Oral composition
GB201320919D0 (en) Composition
GB201317388D0 (en) Composition
GB201306984D0 (en) Composition
PL3042658T3 (pl) Kompozycja lecznicza poprawiająca leptynooporność
GB201317196D0 (en) Composition
SG11201601477VA (en) Pharmaceutical composition
TWI562776B (en) Pharmaceutical composition and uses thereof
GB201307622D0 (en) Composition
SG11201506778QA (en) Plasticizing composition
GB201308933D0 (en) Paediatric composition
GB201301979D0 (en) New composition and use thereof
EP2977051A4 (en) GINSENOSIDZUSAMMENSETZUNG
GB201308502D0 (en) Composition
IL244365A0 (en) pharmaceutical preparation
GB201318394D0 (en) Composition